Adlai Nortye Ltd ADR (ANL)

Currency in USD
13.25
-2.43(-15.50%)
Closed·
13.16-0.09(-0.68%)
·
ANL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.2015.48
52 wk Range
0.8815.79
Key Statistics
Prev. Close
15.68
Open
15.4
Day's Range
7.2-15.48
52 wk Range
0.88-15.79
Volume
1.11M
Average Vol. (3m)
682.87K
1-Year Change
533.9713%
Book Value / Share
-0.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.33
Upside
+113.84%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Adlai Nortye Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally. Its lead product is AN8025, a tri-functional fusion protein of aPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor. The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancreatic, lung, and colorectal adenocarcinomas; and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which is in phase 1b treatment for tumor to activate cancer immunity. It is also developing AN0025, a small molecule EP4 antagonist, which is in phase 1b clinical trials for the treatment of locally advanced esophageal cancer (+chemoradiation therapy), and radiotherapy which is in phase 2 clinical trials for the treatment of rectal cancer (+chemoradiation therapy). Adlai Nortye Ltd. was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Compare ANL to Peers and Sector

Metrics to compare
ANL
Peers
Sector
Relationship
P/E Ratio
−14.8x−4.9x−0.5x
PEG Ratio
−0.520.050.00
Price / Book
−63.1x4.7x2.6x
Price / LTM Sales
97.2x24.0x3.2x
Upside (Analyst Target)
46.7%87.4%47.6%
Fair Value Upside
Unlock−6.2%6.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.33
(+113.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy23.00+73.58%-New CoverageMar 20, 2026
H.C. Wainwright
Buy16.00+20.75%-UpgradeFeb 13, 2026
Lucid Capital Markets
Buy11.00-16.98%-New CoverageJan 29, 2026
H.C. Wainwright
Hold---DowngradeJun 02, 2025

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.23 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ANL Income Statement

People Also Watch

1.28
TMDE
-3.76%
142.520
AAOI
-2.64%
7.60
FIEE
+1.88%
3.30
BATL
-1.49%

FAQ

What Is the Adlai Nortye ADR (ANL) Stock Price Today?

The Adlai Nortye ADR stock price today is 13.25 USD.

What Stock Exchange Does Adlai Nortye ADR Trade On?

Adlai Nortye ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Adlai Nortye ADR?

The stock symbol for Adlai Nortye ADR is "ANL."

What Is the Adlai Nortye ADR Market Cap?

As of today, Adlai Nortye ADR market cap is 578.60M USD.

What Is Adlai Nortye ADR's Earnings Per Share (TTM)?

The Adlai Nortye ADR EPS (TTM) is -1.11.

When Is the Next Adlai Nortye ADR Earnings Date?

Adlai Nortye ADR will release its next earnings report on Jun 03, 2026.

From a Technical Analysis Perspective, Is ANL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Adlai Nortye ADR Stock Split?

Adlai Nortye ADR has split 0 times.

How Many Employees Does Adlai Nortye ADR Have?

Adlai Nortye ADR has 123 employees.

What is the current trading status of Adlai Nortye ADR (ANL)?

As of Apr 15, 2026, Adlai Nortye ADR (ANL) is trading at a price of 13.25 USD, with a previous close of 15.68 USD. The stock has fluctuated within a day range of 7.20 USD to 15.48 USD, while its 52-week range spans from 0.88 USD to 15.79 USD.

What Is Adlai Nortye ADR (ANL) Price Target According to Analysts?

The average 12-month price target for Adlai Nortye ADR is 28.33 USD, with a high estimate of 46 USD and a low estimate of 16 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +113.84% Upside potential.

What Is the ANL Premarket Price?

ANL's last pre-market stock price is 15.29 USD. The pre-market share volume is 5,080.00, and the stock has decreased by -0.39, or -2.49%.

What Is the ANL After Hours Price?

ANL's last after hours stock price is 13.16 USD, the stock has decreased by -0.09, or -0.68%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.